Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae657 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Elise Pesonel und 27 weiteren Autor:innen. Beteiligte Einrichtung: International Severe Acute Respiratory and Emerging Infection Consortium-Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Mpox, Monkeypox, Monkeypox virus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, UK Foreign, Commonwealth and Development Office, Wellcome.
Abstract (Originalsprache)
Background
The global mpox outbreak that started in May 2022 was caused by a novel clade IIb variant of the mpox virus (Orthopoxvirus monkeypox, MPXV). It differed from the traditional Western and Central Africa disease in transmission patterns and clinical presentation.
Methods
To address the need for detailed clinical and virologic data, we conducted an observational cohort study (MOSAIC) during May 2022–July 2023 in individuals with confirmed MPXV infection enrolled in 6 European countries. Case management decisions were left to the attending physician. Participants were monitored for up to 6 months for clinical signs/symptoms and clinical and virologic outcomes through hospital visits, phone interviews, and self-administered questionnaires. Outcomes included time to lesion resolution, clinical status, and virus clearance.
Results
The 518 participants not receiving any specific treatment (“untreated”) were diagnosed a median 5 days from symptom onset; 90% were managed as outpatients. Lesions were mostly cutaneous (88%) and perigenital (74%). By day 14 from the first polymerase chain reaction (PCR)–positive sample, 39% had resolved lesions. Time to 95% unculturable virus was longest in cutaneous lesions (52 days). A putative systemic antiviral was available for 57 participants, 44% as inpatients; 34% and 58% had resolved lesions by day 14 from the first PCR-positive sample and from treatment start, respectively. Time to 95% unculturable virus was 60 days in skin and oropharynx. No death or recrudescence occurred by day 180.
Conclusions
MOSAIC provides comprehensive insights into the clinical and virologic characteristics of mpox caused by the clade IIb variant. The study forms the basis of clinical characterization for ongoing mpox outbreaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- International Severe Acute Respiratory and Emerging Infection Consortium-Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
- Department of Epidemiology Biostatistics and Clinical Research, Assistance Publique-Hôpitaux de Paris (AP-HP) Nord, Hôpital Bichat, Paris, France.
- Infections, Antimicrobials, Modelling, Evolution (IAME) Research Centre, Unité mixte de recherche(UMR) 1137,Université Paris Cité, Institut national de la santé et de la recherche médicale (INSERM), Paris, France.
- HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
- INSERM, National Agency for Research on AIDS and Viral Hepatitis-Emerging Infectious Diseases, Paris, France.
- Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
ORCID-Profile: Elise Pesonel, Laetitia Guiraud, Josephine Bourner, Isabelle Hoffmann, Diana Molino, Coralie Tardivon, Delphine Bachelet, France Mentré, Alain Amstutz, Laura Merson, Amanda Rojek, Minerva Cervantes Gonzalez, Andrea Antinori, Antonella Castagna, Silvia Nozza, Valérie Pourcher, Agnès Libois, Jake Dunning, Evelina Tacconelli, Maya Hites, Fernando De La Calle Prieto, Peter Horby, Yazdan Yazdanpanah, Alexandra Calmy, François-Xavier Lescure, Piero Olliaro
Förderung
- Bill & Melinda Gates Foundation
- UK Foreign, Commonwealth and Development Office
- Wellcome
- Wellcome Trust
- MPX-Response
Zitieren
APA
Pesonel, E., Laouénan, C., Guiraud, L., Bourner, J., Hoffmann, I., Molino, D., Tardivon, C., Bachelet, D., Mentré, F., Amstutz, A., Merson, L., Rojek, A., Cervantes Gonzalez, M., Antinori, A., Castagna, A., Nozza, S., Pourcher, V., Libois, A., Dunning, J., …, & Mpox ObServAtIonal Cohort (MOSAIC) Study Group (2025). Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae657
Vancouver
Pesonel E, Laouénan C, Guiraud L, Bourner J, Hoffmann I, Molino D, et al. Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC). Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae657
BibTeX
@article{Pesonel2025,
author = {Pesonel, Elise and Laouénan, Cédric and Guiraud, Laetitia and Bourner, Josephine and Hoffmann, Isabelle and Molino, Diana and Tardivon, Coralie and Bachelet, Delphine and Mentré, France and Amstutz, Alain and Merson, Laura and Rojek, Amanda and Cervantes Gonzalez, Minerva and Antinori, Andrea and Castagna, Antonella and Nozza, Silvia and Pourcher, Valérie and Libois, Agnès and Dunning, Jake and Tacconelli, Evelina and Hites, Maya and De La Calle Prieto, Fernando and Horby, Peter and Yazdanpanah, Yazdan and Calmy, Alexandra and Lescure, François-Xavier and Olliaro, Piero and Mpox ObServAtIonal Cohort (MOSAIC) Study Group, Mpox ObServAtIonal Cohort (MOSAIC) Study Group},
title = {Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae657}
}
EUVIMED